SI2978759T1 - Derivati benzimidazolona kot bromdomenski inhibitorji - Google Patents

Derivati benzimidazolona kot bromdomenski inhibitorji

Info

Publication number
SI2978759T1
SI2978759T1 SI201430191A SI201430191A SI2978759T1 SI 2978759 T1 SI2978759 T1 SI 2978759T1 SI 201430191 A SI201430191 A SI 201430191A SI 201430191 A SI201430191 A SI 201430191A SI 2978759 T1 SI2978759 T1 SI 2978759T1
Authority
SI
Slovenia
Prior art keywords
bromodomain inhibitors
benzimidazolone derivatives
benzimidazolone
derivatives
bromodomain
Prior art date
Application number
SI201430191A
Other languages
English (en)
Inventor
Evangelos Aktoudianakis
Gregory Chin
Britton Kenneth Corkey
Jinfa Du
Kristyna Elbel
Robert H. Jiang
Tetsuya Kobayashi
Ruben Martinez
Samuel E. Metobo
Michael Mish
Sophie Shevick
David Sperandio
Hai Yang
Jeff Zablocki
Original Assignee
Gilead Sciences, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gilead Sciences, Inc. filed Critical Gilead Sciences, Inc.
Publication of SI2978759T1 publication Critical patent/SI2978759T1/sl

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Epidemiology (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
SI201430191A 2013-03-28 2014-03-27 Derivati benzimidazolona kot bromdomenski inhibitorji SI2978759T1 (sl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201361805995P 2013-03-28 2013-03-28
US201361860230P 2013-07-30 2013-07-30
PCT/US2014/032031 WO2014160873A1 (en) 2013-03-28 2014-03-27 Benzimidazolone derivatives as bromodomain inhibitors
EP14729114.0A EP2978759B1 (en) 2013-03-28 2014-03-27 Benzimidazolone derivatives as bromodomain inhibitors

Publications (1)

Publication Number Publication Date
SI2978759T1 true SI2978759T1 (sl) 2017-05-31

Family

ID=50897885

Family Applications (1)

Application Number Title Priority Date Filing Date
SI201430191A SI2978759T1 (sl) 2013-03-28 2014-03-27 Derivati benzimidazolona kot bromdomenski inhibitorji

Country Status (35)

Country Link
US (2) US20160031868A1 (sl)
EP (1) EP2978759B1 (sl)
JP (1) JP6339175B2 (sl)
KR (1) KR101847698B1 (sl)
CN (1) CN105102453B (sl)
AP (1) AP2015008741A0 (sl)
AU (1) AU2014241152B2 (sl)
BR (1) BR112015024078A2 (sl)
CA (1) CA2907502C (sl)
CL (1) CL2015002871A1 (sl)
CR (1) CR20150515A (sl)
CY (1) CY1119165T1 (sl)
DK (1) DK2978759T3 (sl)
EA (1) EA029497B1 (sl)
ES (1) ES2626397T3 (sl)
HK (1) HK1220692A1 (sl)
HR (1) HRP20170750T1 (sl)
HU (1) HUE034772T2 (sl)
IL (1) IL241186A0 (sl)
LT (1) LT2978759T (sl)
MD (1) MD4531C1 (sl)
MX (1) MX2015013798A (sl)
MY (1) MY176634A (sl)
NZ (1) NZ711586A (sl)
PE (1) PE20151982A1 (sl)
PH (1) PH12015502246A1 (sl)
PL (1) PL2978759T3 (sl)
PT (1) PT2978759T (sl)
RS (1) RS56050B1 (sl)
SG (1) SG11201507926RA (sl)
SI (1) SI2978759T1 (sl)
TW (1) TWI530499B (sl)
UY (1) UY35516A (sl)
WO (1) WO2014160873A1 (sl)
ZA (1) ZA201506356B (sl)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2118074T3 (pl) 2007-02-01 2014-06-30 Resverlogix Corp Związki chemiczne do celów profilaktyki i leczenia chorób układu sercowo-naczyniowego
EP2408454A2 (en) 2009-03-18 2012-01-25 Resverlogix Corp. Novel anti-inflammatory agents
KR102011641B1 (ko) 2011-11-01 2019-08-19 리스버로직스 코퍼레이션 치환된 퀴나졸리논을 위한 경구 즉시 방출 제형
WO2014080290A2 (en) 2012-11-21 2014-05-30 Rvx Therapeutics Inc. Cyclic amines as bromodomain inhibitors
US9765039B2 (en) 2012-11-21 2017-09-19 Zenith Epigenetics Ltd. Biaryl derivatives as bromodomain inhibitors
MX2015007921A (es) 2012-12-21 2016-03-03 Zenith Epigenetics Corp Compuestos heterociclicos novedosos como inhibidores de bromodominio.
TWI719464B (zh) 2013-03-15 2021-02-21 美商英塞特控股公司 作為bet蛋白抑制劑之三環雜環
WO2015004534A2 (en) * 2013-06-21 2015-01-15 Zenith Epigenetics Corp. Novel substituted bicyclic compounds as bromodomain inhibitors
WO2015002754A2 (en) 2013-06-21 2015-01-08 Zenith Epigenetics Corp. Novel bicyclic bromodomain inhibitors
EP3019502B1 (en) 2013-07-08 2017-05-17 Incyte Holdings Corporation Tricyclic heterocycles as bet protein inhibitors
US9855271B2 (en) 2013-07-31 2018-01-02 Zenith Epigenetics Ltd. Quinazolinones as bromodomain inhibitors
WO2015081189A1 (en) 2013-11-26 2015-06-04 Incyte Corporation Bicyclic heterocycles as bet protein inhibitors
US9399640B2 (en) 2013-11-26 2016-07-26 Incyte Corporation Substituted pyrrolo[2,3-c]pyridines and pyrazolo[3,4-c]pyridines as BET protein inhibitors
WO2015095492A1 (en) 2013-12-19 2015-06-25 Incyte Corporation Tricyclic heterocycles as bet protein inhibitors
DK3674302T3 (da) 2014-04-23 2023-04-03 Incyte Holdings Corp 1h-pyrrolo[2,3-c]pyridin-7(6h)-oner og pyrazolo[3,4-c]pyridin-7(6h)-oner som inhibitorer af bet-proteiner
US9527864B2 (en) 2014-09-15 2016-12-27 Incyte Corporation Tricyclic heterocycles as BET protein inhibitors
WO2016061144A1 (en) 2014-10-14 2016-04-21 The Regents Of The University Of California Use of cdk9 and brd4 inhibitors to inhibit inflammation
CA2966303A1 (en) 2014-12-01 2016-06-09 Zenith Epigenetics Ltd. Substituted pyridines as bromodomain inhibitors
EP3227281A4 (en) 2014-12-01 2018-05-30 Zenith Epigenetics Ltd. Substituted pyridinones as bromodomain inhibitors
JP2017537946A (ja) 2014-12-11 2017-12-21 ゼニス・エピジェネティクス・リミテッドZenith Epigenetics Ltd. ブロモドメイン阻害剤としての置換複素環
CA2966450A1 (en) 2014-12-17 2016-06-23 Olesya KHARENKO Inhibitors of bromodomains
JO3789B1 (ar) 2015-03-13 2021-01-31 Resverlogix Corp التراكيب والوسائل العلاجية المعتمدة لمعالجة الامراض المتعلقة بالمتممة
GB201504689D0 (en) 2015-03-19 2015-05-06 Glaxosmithkline Ip Dev Ltd Chemical compounds
GB201504694D0 (en) 2015-03-19 2015-05-06 Glaxosmithkline Ip Dev Ltd Covalent conjugates
WO2016203335A1 (en) 2015-06-18 2016-12-22 Pfizer Inc. Novel pyrido[2,3-b]pyrazinones as bet-family bromodomain inhibitors
WO2017075377A1 (en) 2015-10-29 2017-05-04 Incyte Corporation Amorphous solid form of a bet protein inhibitor
US11225481B2 (en) 2015-12-29 2022-01-18 Centre National De La Recherche Scientifique Xanthine derivative inhibitors of BET proteins
KR102643344B1 (ko) 2016-06-20 2024-03-07 인사이트 코포레이션 Bet 저해제의 결정질 고체 형태
WO2018097976A1 (en) * 2016-11-22 2018-05-31 Gilead Sciences, Inc. Synthesis of a compound that modulates the activity of bromodomain-containing proteins
WO2019086712A1 (en) 2017-11-06 2019-05-09 Centre National De La Recherche Scientifique Xanthine derivatives and uses thereof as inhibitors of bromodomains of bet proteins
IL275478B1 (en) * 2017-12-20 2024-02-01 Betta Pharmaceuticals Co Ltd A preparation that functions as a bromodomain protein inhibitor, and the composition
JP7394140B2 (ja) * 2019-02-02 2023-12-07 シーエスピーシー ゾンチー ファーマシューティカル テクノロジー(シージアチュアン)カンパニー,リミテッド 標的ユビキチン化分解brd4タンパク質化合物、その調製方法および応用
CN109912584B (zh) * 2019-03-22 2021-08-13 中国药科大学 一种具有抗肿瘤活性的brd4蛋白抑制剂及其制备方法和应用
EP4039333A4 (en) 2019-09-30 2024-02-14 Kyowa Kirin Co Ltd BET DEGRADATION AGENT
BR112022023559A2 (pt) * 2020-05-21 2023-01-24 Stemsynergy Therapeutics Inc Inibidores de notch e seus usos
US11833155B2 (en) 2020-06-03 2023-12-05 Incyte Corporation Combination therapy for treatment of myeloproliferative neoplasms

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3845770A (en) * 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US4326525A (en) 1980-10-14 1982-04-27 Alza Corporation Osmotic device that improves delivery properties of agent in situ
US5364620A (en) * 1983-12-22 1994-11-15 Elan Corporation, Plc Controlled absorption diltiazem formulation for once daily administration
US5023252A (en) * 1985-12-04 1991-06-11 Conrex Pharmaceutical Corporation Transdermal and trans-membrane delivery of drugs
US4992445A (en) * 1987-06-12 1991-02-12 American Cyanamid Co. Transdermal delivery of pharmaceuticals
US5001139A (en) * 1987-06-12 1991-03-19 American Cyanamid Company Enchancers for the transdermal flux of nivadipine
US4902514A (en) * 1988-07-21 1990-02-20 Alza Corporation Dosage form for administering nilvadipine for treating cardiovascular symptoms
US6162804A (en) 1997-09-26 2000-12-19 Merck & Co., Inc. Tyrosine kinase inhibitors
EP1620413A2 (en) 2003-04-30 2006-02-01 Cytokinetics, Inc. Compounds, compositions, and methods
GB0420719D0 (en) 2004-09-17 2004-10-20 Addex Pharmaceuticals Sa Novel allosteric modulators
EP2187883A2 (en) 2007-08-10 2010-05-26 Genelabs Technologies, Inc. Nitrogen containing bicyclic chemical entities for treating viral infections
US20100204265A1 (en) 2009-02-09 2010-08-12 Genelabs Technologies, Inc. Certain Nitrogen Containing Bicyclic Chemical Entities for Treating Viral Infections
GB0919423D0 (en) 2009-11-05 2009-12-23 Glaxosmithkline Llc Novel compounds
EP2681200A4 (en) 2011-03-03 2015-05-27 Zalicus Pharmaceuticals Ltd INHIBITORS OF BENZIMIDAZOLE TYPE OF SODIUM CHANNEL
GB201114103D0 (en) * 2011-08-17 2011-09-28 Glaxosmithkline Llc Novel compounds
WO2015002754A2 (en) * 2013-06-21 2015-01-08 Zenith Epigenetics Corp. Novel bicyclic bromodomain inhibitors

Also Published As

Publication number Publication date
HK1220692A1 (zh) 2017-05-12
AU2014241152B2 (en) 2016-11-03
BR112015024078A2 (pt) 2017-07-18
US20140296246A1 (en) 2014-10-02
NZ711586A (en) 2016-09-30
ES2626397T3 (es) 2017-07-24
MX2015013798A (es) 2016-02-16
CA2907502C (en) 2018-02-27
EP2978759A1 (en) 2016-02-03
PT2978759T (pt) 2017-05-31
CA2907502A1 (en) 2014-10-02
MD20150104A2 (ro) 2016-02-29
KR101847698B1 (ko) 2018-04-10
MY176634A (en) 2020-08-19
EA029497B1 (ru) 2018-04-30
RS56050B1 (sr) 2017-09-29
HRP20170750T1 (hr) 2017-07-28
PE20151982A1 (es) 2016-01-28
AP2015008741A0 (en) 2015-09-30
SG11201507926RA (en) 2015-10-29
HUE034772T2 (en) 2018-02-28
TWI530499B (zh) 2016-04-21
CR20150515A (es) 2015-12-01
US9255089B2 (en) 2016-02-09
CN105102453B (zh) 2018-04-06
JP2016515584A (ja) 2016-05-30
PL2978759T3 (pl) 2017-08-31
MD4531C1 (ro) 2018-06-30
JP6339175B2 (ja) 2018-06-06
PH12015502246A1 (en) 2016-02-01
TW201504233A (zh) 2015-02-01
WO2014160873A1 (en) 2014-10-02
MD4531B1 (ro) 2017-11-30
LT2978759T (lt) 2017-05-25
CL2015002871A1 (es) 2016-05-13
US20160031868A1 (en) 2016-02-04
CY1119165T1 (el) 2018-02-14
UY35516A (es) 2014-09-30
ZA201506356B (en) 2017-08-30
EP2978759B1 (en) 2017-03-15
AU2014241152A1 (en) 2015-09-17
IL241186A0 (en) 2015-11-30
KR20150135476A (ko) 2015-12-02
DK2978759T3 (da) 2017-06-19
EA201591455A1 (ru) 2016-01-29
CN105102453A (zh) 2015-11-25

Similar Documents

Publication Publication Date Title
HK1220692A1 (zh) 作為布羅莫結構域抑制劑的苯並咪唑酮衍生物
HK1222646A1 (zh) 作為溴結構域抑制劑的苯並咪唑衍生物
IL256946B (en) Bromodomain inhibitors
HK1224297A1 (zh) 布羅莫結構域抑制劑
IL241123A0 (en) Dihydro-pyrrolopyridinones as inhibitors of bromo sites
HK1223090A1 (zh) -氮雜吲哚衍生物